rs119463990
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001079802.2(FKTN):c.139C>T(p.Arg47Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000868 in 1,612,354 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001079802.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FKTN | NM_001079802.2 | c.139C>T | p.Arg47Ter | stop_gained | 4/11 | ENST00000357998.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FKTN | ENST00000357998.10 | c.139C>T | p.Arg47Ter | stop_gained | 4/11 | 5 | NM_001079802.2 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.00000658 AC: 1AN: 151938Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251276Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135812
GnomAD4 exome AF: 0.00000890 AC: 13AN: 1460416Hom.: 0 Cov.: 29 AF XY: 0.0000124 AC XY: 9AN XY: 726660
GnomAD4 genome ? AF: 0.00000658 AC: 1AN: 151938Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74174
ClinVar
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 17, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 31, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Sep 24, 2021 | This variant is expected to result in the loss of a functional protein. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 21, 2019 | Reported in conjunction with a second missense variant in the FKTN gene in a 7 year old boy with proximal muscle weakness, calf muscle hypertrophy, post-exercise myalgia, and elevated creatinine kinase levels (Vuillaumier-Barrot et al., 2009); Reported as a presumably de novo variant in a Greek/Croatian female with Walker-Warburg syndrome who also harbored a second maternally inherited FKTN variant, although the authors do not comment on phase of the variants (Yis et al., 2011); Reported in ClinVar as a pathogenic variant (ClinVar Variant ID# 3200; Landrum et al., 2016); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 30564623, 9690476, 25814170, 20961758, 19179078, 11165248, 24144914, 23582336, 21191726, 23891399, 25525159, 19842201) - |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 23, 1998 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 10, 2021 | Variant summary: FKTN c.139C>T (p.Arg47X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.6e-05 in 251276 control chromosomes. c.139C>T has been reported in the literature in multiple individuals affected with Fukuyama congenital muscular dystrophy (FCMD) (example, Kobayashi_1998, Vuillaumier-Barrot_2009, Xiong_2009, Yang_2015, Kitamura_2016) and at-least one patient with Walker-Warburg syndrome (WWS) (example, Yis_2011). These data indicate that the variant is very likely to be associated with disease. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Walker-Warburg congenital muscular dystrophy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Oct 04, 2023 | This sequence change creates a premature translational stop signal (p.Arg47*) in the FKTN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FKTN are known to be pathogenic (PMID: 17044012, 17878207, 18752264). This variant is present in population databases (rs119463990, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with Fukuyama-type congenital muscular dystrophy (PMID: 9690476, 19842201; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 3200). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 26, 2021 | - - |
Dilated cardiomyopathy 1X Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Apr 27, 2023 | - - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 14, 2023 | The p.R47* pathogenic mutation (also known as c.139C>T), located in coding exon 2 of the FKTN gene, results from a C to T substitution at nucleotide position 139. This changes the amino acid from an arginine to a stop codon within coding exon 2. This variant has co-occurred with other mutations in the FKTN gene in several individuals with muscular dystrophy phenotypes, including in trans co-occurrences (Kobayashi K et al. Nature, 1998 Jul;394:388-92; Matsumoto H et al. Neuromuscul Disord, 2005 May;15:342-8; Vuillaumier-Barrot S et al. Neuromuscul Disord, 2009 Mar;19:182-8; Xiong H et al. Am J Med Genet A, 2009 Nov;149A:2403-8; Kondo H et al. Jpn J Ophthalmol, 2010 Nov;54:622-4; Yis U et al. Neuromuscul Disord, 2011 Jan;21:20-30; Kobayashi K et al. J Hum Genet, 2017 Nov;62:945-948). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at